XA [gngm]
Inhibition [menp]
Coagulation [ortf]
activity [dora]
influential [idcn]
Prolonged [tmco]
Dalteparin [carb, phsu]
treatment [ftcn]
Gender [orga]
Patients [podg]
Acute Coronary Syndrome [dsyn]
Health [idcn]
Individual [popg]
Background [cnce]
Evaluated [ftcn]
Coagulation [ortf]
activity [dora]
Gender [orga]
Patients [podg]
Syndromes, Acute Coronary [dsyn]
Health [idcn]
Individual [popg]
Similar [qlco]
Age [orga]
Coagulation [ortf]
activity [dora]
Levels [qlco]
XA [gngm]
Inhibition [menp]
Dalteparin [carb, phsu]
treatment [ftcn]
Methods [inpr]
serial [inpr, mnob]
blood samples [bdsu]
Obtained [ftcn]
Women [popg]
Patients [podg]
Scandinavian [popg]
Ii [aapp]
Study [mnob]
Single [popg]
Sample [sbst]
Women [popg]
Health [idcn]
Age [orga]
Sex [orgf]
matched [resa]
Individual [popg]
Randomization [resa]
Patients [podg]
Received [qlco]
Dalteparin [carb, phsu]
IU/kg [qnco]
Maximum [qnco]
IU [qnco]
Twice daily [tmco]
placebo [topp]
N NOS [aapp, imft]
Sex [orgf]
weight [orga]
Adjusted [ftcn]
Doses [qnco]
Dalteparin [carb, phsu]
IU [qnco]
Twice daily [tmco]
N NOS [aapp, imft]
Result [ftcn]
Randomization [resa]
Patients [podg]
OPEN LABEL [resa]
anticoagulation [topp]
Unfractionated Heparin [bacs, carb, phsu]
Dalteparin [carb, phsu]
Therapeutic [topp]
anti-xa [carb, phsu]
Levels [qlco]
IU/mL [qnco]
Found [qnco]
Dalteparin [carb, phsu]
treated [topp]
Patients [podg]
Randomization [resa]
weeks [tmco]
To [qlco]
Lower [spco]
Levels [qlco]
Coagulation [ortf]
activity [dora]
Factor [ftcn]
Vila [euka]
D-dimer [aapp, bacs]
Prolonged [tmco]
treatment [ftcn]
female patients [orga]
High [qlco]
anti-xa [carb, phsu]
Levels [qlco]
Men [popg]
Randomization [resa]
median [spco]
IU/mL [qnco]
P NOS [aapp, imft]
At [spco]
days [tmco]
IU/mL [qnco]
P NOS [aapp, imft]
female patients [orga]
High [qlco]
Levels [qlco]
Coagulation [ortf]
Marker [clna]
Randomization [resa]
weeks [tmco]
months [tmco]
Health [idcn]
Women [popg]
High [qlco]
Levels [qlco]
median [spco]
nmol/L [qnco]
D-dimer [aapp, bacs]
Levels [qlco]
Men [popg]
mU/L [qnco]
g% [qnco]
P NOS [aapp, imft]
Conclusions [idcn]
weight [orga]
Adjusted [ftcn]
female patients [orga]
Reach [orgf]
High [qlco]
anti-xa [carb, phsu]
Levels [qlco]
Suggest [idcn]
INCREASED SENSITIVITY [phpr]
Dalteparin [carb, phsu]
treatment [ftcn]
Health [idcn]
Women [popg]
female patients [orga]
High [qlco]
Coagulation [ortf]
activity [dora]
Increase [ftcn]
Risk [qlco]
Thrombus [patf]
formation [biof]
Large [qnco]
Proportion [qnco]
Patients [podg]
anti-xa [carb, phsu]
Prolonged [tmco]
Dalteparin [carb, phsu]
treatment [ftcn]
reflect [menp]
Poor [grpa]
Compliance [qnco]
Contribute [acty]
Gradual [qlco]
Loss [qnco]
Clinical [qlco]
Efficacy [qlco]
